Advanced Search

Technical Analysis for AYLA - Ayala Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 13.33 -0.30% -0.04
AYLA closed down 0.3 percent on Friday, July 31, 2020, on 12 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
0 Watchers
Watchlist Portfolio

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Up Up
Historical AYLA trend table...
Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.30%
Narrow Range Bar Range Contraction -0.30%
Outside Day Range Expansion -0.30%
Wide Bands Range Expansion -0.30%
Overbought Stochastic Strength -0.30%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.37%
Older EOD signals for AYLA ...
View Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators Basic chart:

Profile

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology. It is focused on the development and commercialization of small molecule therapeutics for patients suffering from rare and aggressive cancers. It also involved in in precision oncology, targeted therapy, drug development, companion diagnostics, and biomarkers. The company was founded in November 2017 and is headquartered in Wilmington, DE.
Medicine Biotechnology Clinical Medicine Drugs Oncology Drug Development Medical Tests Targeted Therapy Precision Medicine Biomarker

Is AYLA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
Jul 27 Ayala Pharmaceuticals to Present Updated Data from Ongoing Phase 2 ACCURACY Trial of AL101 for the Treatment of R/M Adenoid Cystic Carcinoma at the European Society for Medical Oncology (ESMO) Virtual Congress 2020
Jun 22 Ayala Pharmaceuticals EPS misses by $0.23, beats on revenue
Jun 22 Ayala Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update
Jun 12 The Daily Biotech Pulse: FDA Nod For Viela, 3 IPOs And Hematology Congress Presentations
Jun 11 The Daily Biotech Pulse: Sorrento Submits EUA Application For Rapid Coronavirus Test, Decision Day For Viela, Lantern Pharma IPO
Jun 10 Why This Ayala Pharmaceuticals Analyst Is Bullish
Jun 1 Ayala Pharmaceuticals to Present at Upcoming Investor Conferences
May 30 The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight
May 30 Stocks To Watch: Warner Music, Cisco, Casinos And Cars
May 12 Ayala Pharmaceuticals Announces Closing of Initial Public Offering
See more AYLA news...

Indicators

Indicator Value
52 Week High 16.5
52 Week Low 9.15
Average Volume 26,061
200-Day Moving Average 0.00
50-Day Moving Average 12.61
20-Day Moving Average 11.69
10-Day Moving Average 12.89
Average True Range 0.73
ADX 28.31
+DI 28.41
-DI 17.16
Chandelier Exit (Long, 3 ATRs ) 11.31
Chandelier Exit (Short, 3 ATRs ) 11.33
Upper Bollinger Band 14.62
Lower Bollinger Band 8.76
Percent B (%b) 0.78
BandWidth 50.12
MACD Line 0.38
MACD Signal Line 0.08
MACD Histogram 0.2974
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.95
Resistance 3 (R3) 13.90 13.66 13.84
Resistance 2 (R2) 13.66 13.50 13.68 13.81
Resistance 1 (R1) 13.49 13.40 13.58 13.54 13.77
Pivot Point 13.25 13.25 13.29 13.27 13.25
Support 1 (S1) 13.08 13.09 13.17 13.13 12.89
Support 2 (S2) 12.84 12.99 12.86 12.85
Support 3 (S3) 12.67 12.84 12.82
Support 4 (S4) 12.72